{"title":"crp -白蛋白淋巴细胞(CALLY)指数在结直肠癌生存中的预后价值:一项多中心回顾性队列研究。","authors":"Mansour Bahardoust, Mohammadsadra Shamohammadi, Negin Danesh, Armaghan Abbasi Garavand, Mohammad Kasra Rezaei, Homan Alipour, Meisam Haghmoradi, Babak Goodarzy, Seyed Hamzeh Mousavie, Adnan Tizmaghz","doi":"10.1007/s12029-025-01307-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) has become one of the major health burdens in the world with high mortality rates, especially at the advanced stages. The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a novel multidimensional biomarker combining systemic inflammation, nutritional status, and immune function. This study evaluated the association between the CALLY index and overall survival (OS) as well as recurrence-free survival (RFS) in colorectal cancer (CRC) patients.</p><p><strong>Methods: </strong>In this retrospective, multicenter cohort study, the medical characteristics of 1447 CRC patients who were treated at one of the medical centers affiliated with two universities of medical sciences between 2012 and 2022 were examined. Patients were divided into two groups based on the CALLY index: ≥ 2 (945 patients) and < 2 (502 patients). Demographic characteristics, tumor characteristics, and pathological findings of the patients were extracted by referring to the patient records.</p><p><strong>Results: </strong>The 5-year OS rate for patients with a CALLY index ≥ 2 was 80.3%, compared to 64.9% for those with a CALLY index < 2 (log-rank test = 68.2, P = 0.001). The multivariate analysis showed that the CALLY index was significantly associated with OS rate of patients, and OS rate was significantly higher in patients with a CALLY index ≥ 2 than in patients with a CALLY index < 2 (HR 0.84, 95% CI 0.73-0.95, P = 0.001). Also, based on these results, the patients' age, mean BMI, tumor size, T stage, TNM stage, presence of metastasis, tumor location, number of involved lymph nodes, colon diseases, adjuvant chemotherapy, platelet level, and pathological tumor differentiation were all significantly associated with survival in CRC patients (P < 0.05).</p><p><strong>Conclusion: </strong>Our study demonstrated that a higher CALLY index is significantly correlated with improved survival outcomes and a reduced risk of recurrence in CRC patients. CALLY index can be helpful as a criterion for predicting the prognosis of patients with CRC.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"183"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic Value of CRP-Albumin-Lymphocyte (CALLY) Index in Colorectal Cancer Survival: A Multicenter Retrospective Cohort Study.\",\"authors\":\"Mansour Bahardoust, Mohammadsadra Shamohammadi, Negin Danesh, Armaghan Abbasi Garavand, Mohammad Kasra Rezaei, Homan Alipour, Meisam Haghmoradi, Babak Goodarzy, Seyed Hamzeh Mousavie, Adnan Tizmaghz\",\"doi\":\"10.1007/s12029-025-01307-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Colorectal cancer (CRC) has become one of the major health burdens in the world with high mortality rates, especially at the advanced stages. The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a novel multidimensional biomarker combining systemic inflammation, nutritional status, and immune function. This study evaluated the association between the CALLY index and overall survival (OS) as well as recurrence-free survival (RFS) in colorectal cancer (CRC) patients.</p><p><strong>Methods: </strong>In this retrospective, multicenter cohort study, the medical characteristics of 1447 CRC patients who were treated at one of the medical centers affiliated with two universities of medical sciences between 2012 and 2022 were examined. Patients were divided into two groups based on the CALLY index: ≥ 2 (945 patients) and < 2 (502 patients). Demographic characteristics, tumor characteristics, and pathological findings of the patients were extracted by referring to the patient records.</p><p><strong>Results: </strong>The 5-year OS rate for patients with a CALLY index ≥ 2 was 80.3%, compared to 64.9% for those with a CALLY index < 2 (log-rank test = 68.2, P = 0.001). The multivariate analysis showed that the CALLY index was significantly associated with OS rate of patients, and OS rate was significantly higher in patients with a CALLY index ≥ 2 than in patients with a CALLY index < 2 (HR 0.84, 95% CI 0.73-0.95, P = 0.001). Also, based on these results, the patients' age, mean BMI, tumor size, T stage, TNM stage, presence of metastasis, tumor location, number of involved lymph nodes, colon diseases, adjuvant chemotherapy, platelet level, and pathological tumor differentiation were all significantly associated with survival in CRC patients (P < 0.05).</p><p><strong>Conclusion: </strong>Our study demonstrated that a higher CALLY index is significantly correlated with improved survival outcomes and a reduced risk of recurrence in CRC patients. CALLY index can be helpful as a criterion for predicting the prognosis of patients with CRC.</p>\",\"PeriodicalId\":15895,\"journal\":{\"name\":\"Journal of Gastrointestinal Cancer\",\"volume\":\"56 1\",\"pages\":\"183\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Gastrointestinal Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12029-025-01307-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastrointestinal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12029-025-01307-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Prognostic Value of CRP-Albumin-Lymphocyte (CALLY) Index in Colorectal Cancer Survival: A Multicenter Retrospective Cohort Study.
Background: Colorectal cancer (CRC) has become one of the major health burdens in the world with high mortality rates, especially at the advanced stages. The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a novel multidimensional biomarker combining systemic inflammation, nutritional status, and immune function. This study evaluated the association between the CALLY index and overall survival (OS) as well as recurrence-free survival (RFS) in colorectal cancer (CRC) patients.
Methods: In this retrospective, multicenter cohort study, the medical characteristics of 1447 CRC patients who were treated at one of the medical centers affiliated with two universities of medical sciences between 2012 and 2022 were examined. Patients were divided into two groups based on the CALLY index: ≥ 2 (945 patients) and < 2 (502 patients). Demographic characteristics, tumor characteristics, and pathological findings of the patients were extracted by referring to the patient records.
Results: The 5-year OS rate for patients with a CALLY index ≥ 2 was 80.3%, compared to 64.9% for those with a CALLY index < 2 (log-rank test = 68.2, P = 0.001). The multivariate analysis showed that the CALLY index was significantly associated with OS rate of patients, and OS rate was significantly higher in patients with a CALLY index ≥ 2 than in patients with a CALLY index < 2 (HR 0.84, 95% CI 0.73-0.95, P = 0.001). Also, based on these results, the patients' age, mean BMI, tumor size, T stage, TNM stage, presence of metastasis, tumor location, number of involved lymph nodes, colon diseases, adjuvant chemotherapy, platelet level, and pathological tumor differentiation were all significantly associated with survival in CRC patients (P < 0.05).
Conclusion: Our study demonstrated that a higher CALLY index is significantly correlated with improved survival outcomes and a reduced risk of recurrence in CRC patients. CALLY index can be helpful as a criterion for predicting the prognosis of patients with CRC.
期刊介绍:
The Journal of Gastrointestinal Cancer is a multidisciplinary medium for the publication of novel research pertaining to cancers arising from the gastrointestinal tract.The journal is dedicated to the most rapid publication possible.The journal publishes papers in all relevant fields, emphasizing those studies that are helpful in understanding and treating cancers affecting the esophagus, stomach, liver, gallbladder and biliary tree, pancreas, small bowel, large bowel, rectum, and anus. In addition, the Journal of Gastrointestinal Cancer publishes basic and translational scientific information from studies providing insight into the etiology and progression of cancers affecting these organs. New insights are provided from diverse areas of research such as studies exploring pre-neoplastic states, risk factors, epidemiology, genetics, preclinical therapeutics, surgery, radiation therapy, novel medical therapeutics, clinical trials, and outcome studies.In addition to reports of original clinical and experimental studies, the journal also publishes: case reports, state-of-the-art reviews on topics of immediate interest or importance; invited articles analyzing particular areas of pancreatic research and knowledge; perspectives in which critical evaluation and conflicting opinions about current topics may be expressed; meeting highlights that summarize important points presented at recent meetings; abstracts of symposia and conferences; book reviews; hypotheses; Letters to the Editors; and other items of special interest, including:Complex Cases in GI Oncology: This is a new initiative to provide a forum to review and discuss the history and management of complex and involved gastrointestinal oncology cases. The format will be similar to a teaching case conference where a case vignette is presented and is followed by a series of questions and discussion points. A brief reference list supporting the points made in discussion would be expected.